不同基因型技术检测病毒学抑制的拉米夫定经治HIV成人 archived 耐药突变
横断面研究纳入102例稳定抗病毒治疗且病毒学抑制≥1年的HIV感染者,比较全血proviral DNA Sanger测序与PBMCs NGS对既往拉米夫定耐药突变的检出能力。既往耐药组Sanger检出率26.9%,NGS在20%、10%、5%、1%阈值下检出率分别为47.9%、64.6%、75%、87.5%;无既往耐药组Sanger检出1/49(2%),NGS(5%阈值)检出8/45(17.8%)。
要点
- Proviral DNA Sanger测序漏检多数既往拉米夫定耐药突变。
- NGS降低阈值可提高既往耐药突变检出率。
- 少数耐药种群临床意义需进一步评估。
核心结论
- Proviral DNA Sanger测序不能检出多数既往拉米夫定耐药突变。
- NGS在较低阈值下提高检出敏感性,但少数耐药种群的相关性需进一步评估。
研究设计与样本
- 横断面研究纳入102例稳定抗病毒治疗且病毒学抑制≥1年的参与者,其中52例有、50例无历史血浆RNA基因型拉米夫定耐药突变。
- 全血proviral DNA行Sanger测序,PBMCs行NGS。
主要发现
- 有既往拉米夫定耐药者中,Sanger检出耐药突变为26.9%。
- 有既往耐药者中,NGS在20%、10%、5%、1%阈值下检出率分别为47.9%、64.6%、75%、87.5%。
- 无历史拉米夫定耐药者中,Sanger检出耐药突变为1/49(2%),NGS(5%阈值)为8/45(17.8%)。
- 多因素模型显示,有拉米夫定耐药史是全人群NGS检出拉米夫定耐药突变的危险因素。
- 有历史耐药者中,较长的HIV诊断时间与NGS阈值>10%[OR 1.10(95%CI:1.00-1.24)]和>5%[OR 1.16(95%CI:1.02-1.32)]下archived突变持续检出相关。
临床怎么用
- 对病毒学抑制的拉米夫定经治者,若需评估既往耐药,应知晓proviral DNA Sanger测序可能漏检多数历史突变。
- NGS可提高历史拉米夫定耐药突变检出,但低阈值 minority 种群的临床意义尚未明确。
局限性
- minority 拉米夫定耐药种群的相关性需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously selected lamivudine resistance-associated mutations (RAMs) may remain archived within the proviral HIV-DNA. OBJECTIVES: To evaluate the ability of proviral DNA genotyping to detect lamivudine RAMs in HIV-1 virologically suppressed participants; the correlation between Sanger and next generation sequencing (NGS); and predictive factors for detection of lamivudine RAMs in proviral DNA. METHODS: Cross-sectional study of participants on stable antiretroviral therapy and suppressed for ≥1 year. Analysis of proviral DNA was performed by Sanger sequencing in whole blood and by NGS in PBMCs. RESULTS: We analysed samples from 102 subjects (52 with and 50 without lamivudine RAMs in historical plasma RNA-genotypes). Among participants with previous lamivudine resistance, Sanger sequencing detected RAMs in 26.9%. Detection rates significantly increased using NGS: 47.9%, 64.6%, 75% and 87.5% with the 20%, 10%, 5% and 1% thresholds, respectively. As for participants without historical lamivudine resistance, Sanger detected the RAMs in 1/49 (2%), and NGS (5% threshold) in 8/45 (17.8%). Multivariate models fitted to the whole population revealed that having a history of lamivudine resistance was a risk factor for detection of lamivudine RAMs by NGS. Among participants with historical lamivudine resistance, multivariate analysis showed that a longer time since HIV diagnosis was associated with persistence of archived mutations by NGS at thresholds of >10% [OR 1.10 (95% CI: 1.00-1.24)] and >5% [OR 1.16 (95% CI: 1.02-1.32)]. CONCLUSIONS: Proviral DNA Sanger sequencing does not detect the majority of historical lamivudine RAMs. NGS increases the sensitivity of detection at lower thresholds, although the relevance of these minority populations with lamivudine RAMs needs further evaluation.
引用
- Montejano R, Dominguez-Dominguez L, de Miguel R, et al. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study). J Antimicrob Chemother. 2021. PMID: 34459889. doi:10.1093/jac/dkab323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。